Lisa D. Cleary

A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer

Ying S. Ting, R. Govindan, Michael S. Rooney, 2020, Cell.

A first-in-human phase 1 study of a novel PARP7 inhibitor RBN-2397 in patients with advanced solid tumors.

T. Yap, G. Falchook, S. Parasuraman, 2021 .

866 RBN-2397, a novel, potent, and selective PARP7 inhibitor, induces tumor-intrinsic type I interferon responses and adaptive immunity in preclinical models and patient tumors

T. Yap, R. Abo, G. Falchook, 2021, Journal for ImmunoTherapy of Cancer.